Resveratrol does not influence metabolic risk markers related to cardiovascular health in overweight and slightly obese subjects: a randomized, placebo-controlled crossover trial

PLoS One. 2015 Mar 19;10(3):e0118393. doi: 10.1371/journal.pone.0118393. eCollection 2015.

Abstract

Background: In vitro and animal studies have shown positive effects of resveratrol on lipid and lipoprotein metabolism, but human studies specifically designed to examine these effects are lacking.

Objective: The primary outcome parameter of this study in overweight and slightly obese subjects was the effect of resveratrol on apoA-I concentrations. Secondary outcome parameters were effects on other markers of lipid and lipoprotein metabolism, glucose metabolism, and markers for inflammation and endothelial function.

Design: This randomized, placebo-controlled crossover study was conducted in 45 overweight and slightly obese men (n = 25) and women (n = 20) with a mean age of 61 ± 7 years. Subjects received in random order resveratrol (150 mg per day) or placebo capsules for 4 weeks, separated by a 4-week wash-out period. Fasting blood samples were collected at baseline and at the end of each intervention period.

Results: Compliance was excellent as indicated by capsule count and changes in resveratrol and dihydroresveratrol concentrations. No difference between resveratrol and placebo was found in any of the fasting serum or plasma metabolic risk markers (mean ± SD for differences between day 28 values of resveratrol vs. placebo: apoA-I; 0.00 ± 0.12 g/L (P = 0.791), apoB100; -0.01 ± 0.11 g/L (P = 0.545), HDL cholesterol; 0.00 ± 0.09 mmol/L (P = 0.721), LDL cholesterol -0.03 ± 0.57 mmol/L (P = 0.718), triacylglycerol; 0.10 ± 0.54 mmol/L (P = 0.687), glucose; -0.08 ± 0.28 mmol/L (P = 0.064), insulin; -0.3 ± 2.5 mU/L (P = 0.516)). Also, no effects on plasma markers for inflammation and endothelial function were observed. No adverse events related to resveratrol intake were observed.

Conclusion: 150 mg of daily resveratrol intake for 4 weeks does not change metabolic risk markers related to cardiovascular health in overweight and slightly obese men and women. Effects on glucose metabolism warrant further study.

Trial registration: ClinicalTrials.gov NCT01364961.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Aged
  • Apolipoprotein A-I / metabolism
  • Biomarkers / metabolism*
  • Cardiovascular Diseases / etiology
  • Cardiovascular Diseases / metabolism*
  • Cross-Over Studies
  • Female
  • Humans
  • Lipid Metabolism / drug effects
  • Lipoproteins / metabolism
  • Male
  • Middle Aged
  • Obesity / complications
  • Obesity / metabolism*
  • Overweight / complications
  • Overweight / metabolism*
  • Resveratrol
  • Stilbenes / pharmacology*

Substances

  • Apolipoprotein A-I
  • Biomarkers
  • Lipoproteins
  • Stilbenes
  • Resveratrol

Associated data

  • ClinicalTrials.gov/NCT01364961

Grant support

The project is funded by TI Food and Nutrition, a public-private partnership on precompetitive research in food and nutrition. The public partners are responsible for the study design, data collection and analysis, decision to publish, and preparation of the manuscript. Trans-resveratrol capsules were provided by DSM Nutritional Products Ltd. (Kaiseraugst, Switzerland).